Qisda Group participated in the Taiwan Medical Technology Expo on December 5. Harry Yang, General Manager of Qisda's Medical Business Group, noted that the company's medical fleet currently consists of 20 companies, all with an average gross profit margin above 30%. He is confident that the goal of reaching NT$30 billion in revenue next year is achievable and may even exceed expectations.

Yang shared that the medical business accounts for 12-13% of the group's total revenue, with the highest gross profit margin among its four major business divisions. The average gross profit margin for the medical sector is around 30-33%, with the pharmacy business also maintaining this range. Notably, the margin for Hongyun hearing aids is as high as 80%.

Looking at overseas markets, China accounts for the largest share of revenue, followed by Southeast Asia. Yang mentioned that the overseas market is mainly focused on medical device products, with China expected to see the highest growth rate next year, especially in the area of blood dialysis.

At the Medical Technology Expo, Qisda showcased its collaborations with 24 partner companies, presenting four key themes: smart healthcare, blood dialysis, medical device consumables, and medical services. The company also highlighted six major AI applications in smart healthcare, covering everything from surgery and clinical practices to pharmacy channels. By incorporating advanced data analysis and precision diagnostic technologies, Qisda aims to further enhance efficiency.

Yang also emphasized that the application of AI in smart healthcare is unstoppable. Integrating AI functionalities into both hardware and software is akin to having a co-pilot with extensive experience, assisting in tasks such as annotation, diagnosis, and reducing time spent on tedious data management. Qisda demonstrated various AI applications at the exhibition and plans to gradually implement these smart AI solutions across multiple fields in the future.

Resource: 〈醫療科技展〉佳世達楊宏培：醫療艦隊逐步壯大 看好明年300億業績達標